Additional Information

Description

Ilumya Spd (100 mg/mL) is a prescription biologic used for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It contains tildrakizumab, a humanized monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23). By inhibiting IL-23, it reduces inflammation and prevents the excessive proliferation of skin cells associated with psoriasis.

The injection is a sterile, preservative-free formulation presented as a clear to slightly opalescent, colorless to slightly yellow solution. It is supplied in a prefilled syringe containing 100 mg of tildrakizumab in 1 mL of solution. The syringe is designed for subcutaneous administration and is intended for use under the supervision of a healthcare professional. 

Ilumya is administered as a 100 mg subcutaneous injection at weeks 0 and 4, followed by maintenance dosing every 12 weeks. This extended dosing interval helps improve patient adherence and reduces the frequency of injections compared to other biologic therapies.